An Experimental Pill Stopped Measles From Spreading in Animals — Even Through the Air

Researchers have shown that an experimental pill can stop a measles-like virus from spreading between animals, including through the air — a result that could give public health officials a tool to snuff out outbreaks in the window when vaccination alone comes too late.

The drug, GHP-88310, is a broad-spectrum inhibitor of viral polymerase, the enzyme a virus needs to copy its own genetic material. Without a working polymerase, the virus cannot reproduce fast enough to build the load required to infect the next person. The compound was developed and tested at Georgia State University's Center for Translational Antiviral Research, with the transmission findings published in Nature Microbiology and a companion characterization of the drug in Science Advances.

Because measles cannot be ethically studied in humans this way, the team used ferrets infected with canine distemper virus, a close relative of measles that produces a similar disease and spreads by the same routes. Animals given the drug shortly before or shortly after exposure did not pass the virus on — not by direct contact and not through airborne transmission, the route that makes measles one of the most contagious pathogens known. When the pill was given to animals that were already infected, it shortened both the duration of illness and the length of time the animals remained contagious.

"Silencing measles outbreaks quickly is essential to reestablish control over the virus," said senior author Richard Plemper, director of the center, framing the drug as a complement to vaccination rather than a replacement for it.

The context is a resurgence that public health officials did not expect to be fighting in 2026. Measles has surged across North America since 2025, driving thousands of infections, hundreds of hospitalizations and multiple deaths, and pushing the United States toward the loss of the elimination status it earned in 2000. Outbreaks typically take hold in communities with low vaccination coverage, and the standard response — ring vaccination plus isolation — struggles against a virus that is infectious for days before the telltale rash appears and can linger in the air of a room for up to two hours after an infected person leaves.

A drug that blocks onward transmission would change the arithmetic of that response. Health departments could treat exposed household members, classmates and hospital contacts during the incubation period, cutting chains of infection that vaccination cannot reach fast enough because immunity takes roughly two weeks to develop. Post-exposure prophylaxis currently relies on the vaccine itself or on immunoglobulin, neither of which reliably halts spread once exposure is widespread.

Significant caveats remain. Ferrets are not people, canine distemper is not measles, and drugs that perform well in animal transmission models routinely disappoint in humans. The Georgia State team is now preparing GHP-88310 for formal human clinical trials, a process that will take years and will have to establish both safety and whether the effect holds in outbreaks driven by human behavior rather than controlled cages.